Immunogenicity and reactogenicity of a pneumococcal conjugate vaccine administered combined with a Haemophilus influenzae type b conjugate vaccine in United Kingdom infants
- 1 September 2000
- journal article
- clinical trial
- Published by Wolters Kluwer Health in The Pediatric Infectious Disease Journal
- Vol. 19 (9) , 854-862
- https://doi.org/10.1097/00006454-200009000-00009
Abstract
Streptococcus pneumoniae is a major disease burden in young children and the incidence of antibiotic-resistant pneumococcal strains is increasing. Multivalent pneumococcal saccharide-protein conjugate vaccines have recently been developed. To assess the immunogenicity and reactogenicity of a 7-valent pneumococcal conjugate vaccine (7VPnC) administered as a separate injection or as a combined injection with Haemophilus influenzae type b vaccine (HbOC) at 2, 3 and 4 months of age. Randomized controlled trial of 368 healthy UK infants receiving routine vaccines only (control group), routine vaccines and 7VPnC as a separate injection (separate group), or routine vaccines and 7VPnC combined with HbOC (combined group) at 2, 3 and 4 months. The control group received 7VPnC at 5, 6 and 7 months. All groups received pneumococcal polysaccharide vaccine at 13 to 16 months. Anticapsular IgG antibodies to 7VPnC serotypes were measured at 2, 5, 13 and 14 months and safety data collected. IgG antibody concentrations at 5 months were higher in the two treatment groups compared with the controls for all 7VPnC serotypes (P < 0.001) and higher in the separate group than the combined group for five 7VPnC serotypes (P < 0.05). For both treatment groups antibody concentrations were higher at 14 months (range, 6.6 to 25.3 μg/ml) than at 5 months (range, 0.6 to 2.5 μg/ml) for all 7VPnC serotypes (P < 0.001). 7VPnC was well-tolerated, safe and immunogenic when administered as a separate or as a combined 7VPnC/HbOC injection. Although antibody responses were lower in the infants who received the combination compared with those who received 7VPnC as a separate injection, marked anamnestic responses to polysaccharide challenge were observed, suggesting that both groups were immunologically primed.Keywords
This publication has 25 references indexed in Scilit:
- Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in childrenThe Pediatric Infectious Disease Journal, 2000
- KINETICS OF BOOSTER RESPONSES TO HAEMOPHILUS INFLUENZAE TYPE B CONJUGATE AFTER COMBINED DIPHTHERIA-TETANUS-ACELLULAR PERTUSSIS-HAEMOPHILUS INFLUENZAE TYPE b VACCINATION IN INFANTSThe Pediatric Infectious Disease Journal, 1999
- Immunogenicity and Impact on Nasopharyngeal Carriage of a Nonavalent Pneumococcal Conjugate VaccineThe Journal of Infectious Diseases, 1999
- The Continued Emergence of Drug-Resistant Streptococcus pneumoniae in the United States: An Update from the Centers for Disease Control and Prevention's Pneumococcal Sentinel Surveillance SystemThe Journal of Infectious Diseases, 1996
- Epidemiology of Invasive Pneumococcal Disease in Southern California: Implications for the Design and Conduct of a Pneumococcal Conjugate Vaccine Efficacy TrialThe Journal of Infectious Diseases, 1996
- Immunogenicity of heptavalent pneumococcal conjugate vaccine in infantsThe Journal of Pediatrics, 1996
- Serotype Distribution of Streptococcus pneumoniae Infections among Preschool Children in the United States, 1978-1994: Implications for Development of a Conjugate VaccineThe Journal of Infectious Diseases, 1995
- Antibody response to pneumococcal capsular polysaccharide vaccine in African childrenThe Pediatric Infectious Disease Journal, 1991
- Prevention ofHaemophilus influenzaeType b Infections in High-Risk Infants Treated with Bacterial Polysaccharide Immune GlobulinNew England Journal of Medicine, 1987
- Prevention ofHemophilus influenzaeType B Bacteremic Infections with the Capsular Polysaccharide VaccineNew England Journal of Medicine, 1984